Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 5/20 | 0.52 |
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | PCSK9 | Q8NBP7 | 5/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 4/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | HCK | P08631 | 1/20 | 0.42 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401253 | 0.84 | LDLR (0.52) | LDLRKITPCSK9MAPK14PDGFRB | |
| SCHEMBL1656109 | 0.80 | KIT (0.62) | LDLRKITPCSK9MAPK14PDGFRB | |
| SCHEMBL6041122 | 0.77 | LCK (0.59) | BTK | |
| SCHEMBL6041102 | 0.75 | BMX (0.46) | KITMAPK14PDGFRBABL1 | |
| SCHEMBL19376721 | 0.73 | ABL1 (0.59) | LDLRKITPCSK9MAPK14PDGFRB | |
| SCHEMBL6041096 | 0.73 | ABL1 (0.45) | KITPDGFRBABL1 | |
| SCHEMBL6041090 | 0.72 | KIT (0.66) | KITMAPK14PDGFRBABL1SRC | |
| SCHEMBL6041150 | 0.69 | ABL1 (0.57) | PDGFRBABL1SRCBTK | |
| SCHEMBL6041103 | 0.69 | ABL1 (0.61) | MAPK14PDGFRBABL1 | |
| SCHEMBL1653887 | 0.69 | ABL1 (0.74) | LDLRKITPCSK9MAPK14PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | LDLR 2348/4885KIT 254/4885PCSK9 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.